BRTX - Company ID 0001505497
BioRestorative Therapies, Inc. trades as BRTX. In its fiscal 2025 annual report the company posted revenue of $359.70K, down 10.3% from the prior year and net income of -$14.24M. This page tracks BioRestorative Therapies, Inc. through 735 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years BioRestorative Therapies, Inc.'s revenue grew from $36.35K to $359.70K, a compound annual growth rate of 29.0%. Net profit margin expanded from -23755.4% to -3959.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-01 |
| 424B3 | - | 2026-04-30 |
| EFFECT | - | 2026-04-28 |
| POS AM | - | 2026-04-27 |
| Major company event | 8-K | 2026-04-23 |
| POS AM | - | 2026-04-20 |
The largest companies sharing BioRestorative Therapies, Inc.'s SEC industry classification (services-misc health & allied services, nec).
BioRestorative Therapies, Inc. reported revenue of $359.70K for fiscal year 2025, a decrease of 10.3% year over year.
In its latest fiscal year BioRestorative Therapies, Inc. reported a net loss of $14.24M.